Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Debio 1562M |
| Synonyms | |
| Therapy Description |
Debio 1562M is an antibody-drug conjugate (ADC) targeting CD37, which potentially decreases growth of CD37-expressing tumor cells (Cancer Res (2025) 85 (8_Supplement_1): 1160). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Debio 1562M | Debio-1562M|Debio1562M | CD37 Antibody 9 | Debio 1562M is an antibody-drug conjugate (ADC) targeting CD37, which potentially decreases growth of CD37-expressing tumor cells (Cancer Res (2025) 85 (8_Supplement_1): 1160). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06969430 | Phase Ib/II | Debio 1562M | A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML) | Recruiting | USA | 0 |